• Japanese
  • Korean
  • Chinese
Cover Image

Autoimmune Disease Therapeutics

Abstract

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.The report profiles 112 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck & Co., Inc, Merck Serono SA, Novartis AG, Sanofi-aventis SA , Shire Plc, Teva Pharmaceuticals Industries Limited, and UCB S.A. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definition and Scope of Study
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Psoriasis
  • Crohn's disease

2. INDUSTRY OVERVIEW & OUTLOOK

  • Autoimmune Disease Therapeutics Market Continues to Flourish
  • Pharmaceutical Industry Hit by Economic Downturn
    • Economic Downturn Takes Toll on R&D
  • Current and Future Analysis
    • Segment Analysis
    • Rheumatoid Arthritis Therapeutics - The Largest Segment
    • Multiple Sclerosis Therapeutics Market
    • Crohn's Disease Therapeutics Market
    • Ulcerative Colitis Drugs Market

3. MARKET DYNAMICS AND TRENDS

  • Biologics Find Acceptance as First Line of Treatment for Autoimmune Diseases
  • High Unmet Need Favors Growth
  • Impact of Biosimilars Legislation on Biologic Arthritis Drugs Market
  • New Products to Drive Market Growth
  • Biogenerics to Expand Adoption of Biological Drugs
  • Risk of Cancer Due to Anti-TNF Drugs
  • Superior Outcomes to Enhance Adoption of Biologics
  • Efficacy and Convenience - Key Factors Driving Physician's Decision

4. DISEASE OVERVIEW

  • Immunity and Immune System
  • Autoimmune Diseases
  • Women- Highly Susceptible to Autoimmune Diseases
    • Table 1: Percentage Breakdown of Incidence of Autoimmune Diseases in Men and Women (includes corresponding Graph/Chart)
  • Complexity in Manifestations Renders Difficulty in Understanding the Conditions
  • Etiology of Autoimmune Diseases
  • Genetic Predisposition
  • Environmental Factors
  • Autoimmune Diseases - A Social and Health Burden
  • Regulatory Glitches and High Costs Hinder Biogenerics
  • Types of Autoimmune Diseases
  • Incidence and Prevalence
  • Diagnosis and Treatment of Autoimmune Diseases
  • Overview on Select Biologic Drugs
  • Remicade
  • Humira
  • Rituxan(r) (rituximab)
  • Cimzia
    • Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market
    • Psoriasis - A Promising Market for Cimzia
  • Actemra
  • Enbrel

5. OVERVIEW OF SELECT AUTOIMMUNE DISEASES

  • Rheumatoid Arthritis
  • Disease Overview
  • Low Penetration to Sustain growth of Anti-TNF Drugs
  • Incidence and Prevalence Higher in Urban and Developed Regions
  • Symptoms and Diagnosis
  • Treatment of Rheumatoid Arthritis
  • BRMs Revolutionize RA Treatment
  • Branded Products
    • Drugs Used in Treating Rheumatoid Arthritis
    • Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy
    • Key Drugs in Late Stage Development for Rheumatoid Arthritis Treatment
  • Competitive Landscape
    • Table 2: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point
  • High Prices and Safety Concerns
  • Multiple Sclerosis
  • Etiology
  • Types of Multiple Sclerosis
    • Table 3: Prevalence of Different Types of Multiple Sclerosis
  • Pathology
    • Prevalence of Multiple Sclerosis High in Women
    • Facts About Multiple Sclerosis
  • Treatment
    • Interferon Drugs - High Efficacy Drugs in Existing MS Therapies
      • Beta Interferon Drugs in Multiple Sclerosis Treatment
    • Non-Interferon Drugs
      • Non-Interferon Drugs in Multiple Sclerosis Treatment
  • Trends in Multiple Sclerosis Market
    • High Unmet Need and Rich Pipeline to Expand MS Market
    • Interferon-based Drugs Lead Multiple Sclerosis Drug Market
    • Oral Drugs Alter Dynamics in MS Therapies Market
    • Dip in Sales Inevitable for Current Therapies
    • Tough Times Ahead for Betaseron
  • Competitive Landscape
    • Table 4: Leading Products/Companies in the Global Multiple Sclerosis Therapeutics Market (2010): Percentage Share Breakdown of Value Sales for Biogen Idec, Teva/sanofi-aventis*, Merck Serono, Bayer Schering, Elan, and Others (includes corresponding Graph/Chart)
  • Multiple Sclerosis Drug Pipeline - An Overview
    • Drugs Under Development for Treating Multiple Sclerosis
    • Fingolimod (Gilenya)
    • Mylinax
    • Laquinimod
    • Campath (Alemtuzumab)
    • Teriflunomide
    • Fampridine-SR
    • BG-12 (Oral Fumarate)
    • MN-166
  • Psoriasis
  • Prevalence
  • Available Treatment Options
    • Biological Drugs
    • Biological Drugs Lead the Fray
    • Potential Therapeutic Products
  • Inflammatory Bowel Diseases
  • Crohn's disease
    • Stages of the Disease
    • Prevalence
    • Diagnosis
    • Treatment
  • Ulcerative Colitis
    • Diagnosis and Treatment
  • Other Diseases
  • Systemic Lupus Erythematosus (SLE)
    • Prevalence and Epidemiology
    • Treatment
  • Sjogren's Syndrome
    • Prevalence and Epidemiology
    • Diagnosis and Treatment
  • Type-1 Diabetes Mellitus
    • Types of Diabetes Mellitus
      • Type 1 or Insulin Dependent Diabetes Mellitus
      • Type 2 or Non-Insulin Dependent Diabetes Mellitus
    • Insulin - Vital for Blood Glucose Management
    • Etiology
    • Prevalence
      • Diabetes in Children - A Growing Concern
    • Diagnosis and Treatment
  • Autoimmune Hepatitis
    • Disease Categories
    • Treatment
    • Side Effects
  • Juvenile Rheumatoid Arthritis
    • Symptoms
    • Diagnosis
  • Scleroderma
    • Prevalence
    • Etiology
    • Diagnosis
    • Management
  • Vasculitis Syndeomes
  • Haematologic Autoimmune Diseases
  • Ankylosing Spondylitis

6. CLINICAL TRIALS & RESEARCH STUDIES

  • Antares Pharma Commences VIBEX MTX Clinical Trial for Treating Rheumatoid Arthritis
  • Avila Therapeutics Introduces Btk Inhibitor for Treating Autoimmune Diseases and Cancer
  • Athersys and Angiotech to Conduct MultiStem(r) Clinical Trial
  • BioMarin Commences Amifampridine Phosphate Clinical Trial for Treating LEMS
  • TxCell Successfully Completes Trial for Crohn's Disease Cell Therapy
  • Novartis Releases Phase II Data for AIN457
  • Sanofi Releases Phase III TEMSO Study Results of Teriflunomide
  • Biogen Achieves Positive Results for BG-12 Drug Trial
  • Innate Therapeutics Commences MIS416 Clinical Trial in Progressive MS Patients
  • Pfizer Completes Clinical Trials for Tasocitinib
  • Compugen Completes Animal Model Study of CGEN-15001
  • Avila Therapeutics Commences AVL-292 Clinical Trial
  • Horizon Pharma Completes Clinical Trials for LODOTRA(r)
  • ChemoCentryx Begins Phase 1 Clinical trial for CCX168
  • NYU Langone Medical Center Announces Potential Therapy for Rheumatoid Arthritis
  • Compugen to Start Preclinical Development for Therapeutic Drugs
  • Avila Therapeutics Begins Phase I Clinical Trial for AVL-292
  • VBL Therapeutics Releases Preclinical Data for VB-201
  • GlaxoSmithKline and Dynavax Select DV1179 for Endosomal TLR Inhibitor Program
  • Idera Pharmaceuticals Starts Phase 1 Clinical Study of IMO-3100
  • ChemoCentryx Begins Phase I Clinical Study of CCX168
  • VBL Therapeutics Starts Phase II Clinical Study of VB-201
  • ChemoCentryx Begins Phase II Clinical Study of CCX354
  • Neovacs Starts Phase IIa Clinical Study of TNF Kinoid
  • Galapagos Begins Phase II Clinical Study of Nanocort
  • Plexxikon Starts Dosing of PLX3397 in Phase I Clinical Study

7. PRODUCT INTRODUCTIONS/APPROVALS

  • Horizon Pharma Receives FDA Approval for DUEXIS(r)
  • Venus Remedies to Launch Trois
  • CNRS/Inserm Researchers Introduce Dendrimer ABP as RA Therapy
  • Food and Drug Monitoring Agency to Approve Tocilizumab for Commercial Use
  • Novartis Bags EC Approval for Gilenya(r)
  • Genentech Obtains FDA Approval for ACTEMRA
  • Novartis Gains Approval for Gilenya in Japan
  • Novartis Receives FDA Approval for Gilenya
  • Compugen Discovers and Validates CGEN-15001 Soluble Recombinant Fusion Protein
  • InNexus Biotechnology Develops IXSCD11a
  • Centocor Ortho Biotech Submits sBLA for Simponi Label Extension
  • Osiris Therapeutics Obtains Orphan Drug Designation for Prochymal from FDA
  • Immunomedics Obtains US Patent for Immunotherapy
  • Biogen Idec Introduces Monoclonal Antibody Tysabri in India
  • Merck Serono Unveils Pre-Filled Pen RebiDose(tm) in UK
  • BioMarin Unveils Firdapse(tm) in European Union
  • Sandoz Introduces Calcipotriene Solution in US
  • Cimzia(r) Receives FDA Approval for Treating Rheumatoid Arthritis
  • Simponi(tm) Receives FDA Approval for Treating Rheumatoid Arthritis
  • Novartis Introduces Extavia(r) for Multiple Sclerosis Treatment in Denmark & Germany
  • Novartis Bags FDA Approval for Extavia
  • UCB Receives EC Approval for Cimzia
  • Centocor Ortho Biotech Receives FDA Approval for Stelara
  • BioMarin Pharmaceutical Bags FDA's Orphan Drug Designation
  • Promius Pharma Introduces Scytera(tm) for Psoriasis Treatment
  • Galderma Receives FDA Approval for Plaque Psoriasis Ointment Vectical(tm)
  • Roche Obtains EC Approval for Rheumatoid Arthritis Antibody RoACTEMRA
  • Viron Therapeutics Obtains US Patents for VT-384, VT-346 Candidates
  • Bayer Schering Pharma Obtains Approval for Betafron(r) Therapy from SFDA
  • US Food and Drug Administration Approves Certolizumab Pegol
  • Nitec Unveils Lodotra(r) in Germany

8. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST - A PERSPECTIVE BUILDER

  • HUMIRA(r) Obtains EU Approval for Polyarticular Juvenile Idiopathic Arthritis
  • Cimzia(r) Receives FDA Nod for Treating Crohn's Disease
  • HUMIRA(r) Obtains Approval from Japanese Ministry for Rheumatoid Arthritis
  • HUMIRA(r) Receives FDA Clerance for Polyarticular Juvenile Idiopathic Arthritis
  • Abbott Receives EU Marketing Authorization for Humira in Psoriasis Treatment
  • Xian-Janssen Introduces Remicade, Branded infliximab in China
  • HUMIRA(r) Obtains EU Approval for Treating Crohn's Disease
  • HUMIRA(r) Obtains FDA Approval for Crohn's Disease
  • Remicade(r) Obtains Approval for Use in PsA and Early RA in Australia
  • Tysabri(tm) Receives Health Canada Approval for Use in Multiple Sclerosis
  • Rituxan(r) Gets FDA Approval for Use in RA
  • Humira(r) Obtains FDA Approval for Treating AS
  • Betaseron(r) Receives FDA Approval for Use in First Clinical Episode of MS
  • Abbott Receives FDA Clearance for HUMIRA Pen
  • Remicade Obtains FDA Approval for Treating Pediatric Crohn`s Disease

9. RECENT INDUSTRY ACTIVITY

  • Sanofi-Aventis Takes over Genzyme
  • Daiichi Sankyo to Acquire Plexxikon
  • TiGenix Takes Over Cellerix
  • Alkermes and Elan Drug Technologies to Merge Operations
  • Pfizer Japan Inks Agreements with Takeda to Co-Promote RA Drugs
  • Viropro Inks Letter of Agreement with Spectrum Pharmaceuticals
  • Pepscan Therapeutics Collaborates with Phylogica
  • Lycera Enters into Research Collaboration with Merck
  • Merck Amends Distribution Agreement with Johnson & Johnson
  • Yale University and Debiopharm Enter into License Agreement for Debio 1036
  • Opexa Therapeutics Inks Agreement with American Red Cross
  • Antitope and NasVax Enter into Research Collaboration
  • SuppreMol Inks In-License Agreement with Bayerische Patentallianz
  • Glenmark Inks License Agreement with Sanofi
  • Exagen Enters into Partnership with Medco
  • Phylogica Inks Research Collaboration and Option Agreement with Pepscan Therapeutics
  • Merck Sharp & Dohme Enters into Partnership with Lycera
  • Amgen Enters into Collaboration with Xencor
  • PhRMA Announces Development of Medicines Targeted Towards Women
  • Circassia Secures Global Development and Marketing Rights to PAP-1 from Airmid
  • UCB Establishes Microbial Production Facility
  • Emergent BioSolutions Takes Over Trubion Pharmaceuticals
  • Gilead Sciences to Takeover CGI Pharmaceuticals
  • Abbott Laboratories Acquires Facet Biotech
  • Merck Takes Over Millipore
  • Quidel to Snap Up Diagnostic Hybrids
  • Nitec Pharma Merges with Horizon Therapeutics
  • Femta Pharmaceuticals Inks Manufacturing Agreement with Lonza Group
  • Horizon Pharma Signs Agreement with Mundipharma International
  • 3SBio Signs Agreement with Isotechnika Pharma
  • Fast Forward and Provid Pharmaceuticals Extend Partnership
  • Antitope and PIKAMAB Collaborate
  • Ligon Discovery Enters into Agreement with Lycera
  • Axxam, Fast Forward and Juvenile Diabetes Research Foundation Enter into Partnership
  • GlaxoSmithKline Collaborates with ChemoCentryx
  • Perseid Signs Agreement with Astellas Pharma for CTLA4-Ig Program
  • Cellceutix Chooses Destum Partners for KM-133 Psoriasis Compound
  • NERC Commences Operations of IXO Therapeutics
  • Avesthagen to Market Avent
  • Isotechnika Pharma Divests Stake in Isodiagnostika
  • MacroGenics Obtains New Grants from NIH
  • AnaptysBio Collaborates with VLST to Generate Novel Antibody Therapeutics
  • AstraZeneca Enters into Exclusive License Agreement with Rigel Pharmaceuticals
  • Immutep Inks License Agreement with GlaxoSmithKline for Therapeutic Antibody IMP731
  • Novo Nordisk Inks Research Collaboration Agreement with Combine
  • Xention and Axxam Enter into Autoimmune Disorder Research Partnership
  • Roche Takes Over Genentech
  • Merck Acquires Schering-Plough
  • Pfizer Takes Over Wyeth
  • Amgen Takes Over Immunex
  • BioMarin Pharmaceutical Takes Over Huxley Pharmaceuticals
  • Onyx to Takeover Proteolix
  • Genzyme Takes Over Global Rights of Campath, Leukine and Fludara from Bayer
  • Bristol-Myers Squibb Enters into Agreement with Alder Biopharmaceuticals
  • LEO Pharma Inks Agreement with Warner Chilcott
  • Kineta One Acquires Commercial Rights for Compounds from Airmid
  • Kineta Signs Agreement with Alturas Analytics
  • Catalyst Biosciences in Research and License Agreement with MedImmune
  • Boehringer Ingelheimes Collaborates with Exelixis
  • Lonza Signs Agreement with Opsona Therapeutics for Manufacturing Antibody
  • Eli Lilly and Incyte Enter into Agreement
  • Novartis Option Fund and Avila Therapeutics Sign Option Agreement
  • Genentech Acquires Rights for BHT-3021 from Bayhill Therapeutics
  • Celentyx and Meiji Seika Kaisha Ink Agreement
  • Exelixis and Boehringer Ingelheim Enter into Autoimmune Disease Partnership
  • Celldex Acquires Exclusive Rights of Immune-Stimulatory Molecules from Amgen
  • Apitope and Merck Serono Sign Agreement for Multiple Sclerosis Drug
  • Biovitrum and Affibody(r) Enter into Collaboration
  • Bayhill Therapeutics Bags Contract from Genentech

10. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER

  • Novo Nordisk and VLST Collaborate on Therapeutic Targets Development
  • Actemra's Approval Gets Delayed
  • Apitope Raises Financing for Developing Multiple Sclerosis Compound
  • CalciMedica to Acquire Rights to STIM1 from TorreyPines
  • Roche Acquires ARIUS Research, Inc.
  • Astellas Inks Agreement with Maxygen for MAXY-4 Candidates
  • Carna and Caliper Life Sciences Ink Collaborative Supply Agreement
  • Isotechnika Gets Back Worldwide Rights to Transplant Drug, Voclosporin
  • Boehringer In-licenses Two Drug Targets from BioFocus
  • Bionomics Enters into a Development and Licensing Agreement with Merck Serono
  • Nycomed Inks Agreement with Immunomedics for Veltuzumab
  • EpiVax Receives Grants from National Institutes of Health to Advance Epi-13
  • Boehringer to Takeover Actimis
  • Antisoma Acquires Xanthus Pharmaceuticals
  • Merrimack Acquires Funds for Developing Cancer and Autoimmune Disease Biologics
  • BioSeek and Merck Sign Collaboration Agreement for Compound Evaluation
  • Questcor Amends Distribution Contract with US Distributor of Acthar
  • ANP Completes Phase IIa Trial for Multiple Sclerosis Drug
  • Insert and Calando Merge to Form Calando Pharmaceuticals
  • Codon Inks Research & Development and Licensing Deal with Merrimack
  • Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK Peptide
  • Chelsea Acquires Global Rights to I-3D Range of DHODH Inhibiting Compounds
  • Cypress Bioscience Acquires Proprius
  • J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals
  • GlaxoSmithKline Acquires License to Market Vaccinex's Antibody
  • Teva to Takeover CoGenesys
  • Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune Diseases
  • Anthera Acquires Rights to Develop and Market AMG 623 from Amgen
  • Can-Fite Enters into Two Cooperation Agreements to Develop CF102 Drug
  • Source MDx Inks an Agreement with Pfizer
  • Cambridge Inks an Antibody Development Agreement with Medarex
  • Pfizer to Acquire Coley Pharma
  • GSK Joins Hands with Tolerx to Develop and Commercialize otelixizumab
  • Amgen Acquires Avidia
  • Eli Lilly and MacroGenics Tie Up for Developing Teplizumab
  • MorphoSys and Genesis Ink Antibody R&D Deal
  • arGentis Enters into a License Agreement with UTRF
  • Eden Biodesign to Investigate Novel Drug Candidate for Autoimmune Diseases
  • Nuon and Kissei Team up for Tranilast
  • Organon and Dyax Team Up for Developing Therapeutic Antibodies
  • Medarex Joins Hands with Mitsubishi for Monoclonal Antibody Development
  • Merck and Archemix Collaborate
  • Genzyme Takes Over Bioenvision
  • Organon and Medarex Ink Drug Development Deal
  • CalciMedica Secures Exclusive Rights for CBR's Autoimmune Drug Target
  • Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway
  • Eisai Corporation Acquires Morphotek
  • TIRC Changes Name to Orchestra Therapeutics
  • Abbott Files HUMIRA(r) for Psoriasis in the US and EU (USA/Europe)
  • Accentia Secures Exclusive Global Rights to Revimmune
  • Medarex and Compugen Ink Collaborative Agreement for Therapeutic Antibody
  • SRI and Telik Sign License Agreement for Drug Development
  • China Biopharma Signs Agreement with Chinese Biopharmaceutical Firm
  • Kirin and Astellas Ink Licensing Agreement for Anti-CD40 Antagonistic mAb
  • QSV and Artielle Sign Contract to Produce RTL-1000
  • JDRF and MacroGenics Form Partnership
  • GSK and Genmad Sign Partnership Agreement for HuMaxCD20
  • Biocon Enters into Joint Venture Agreement with Neopharma
  • Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals
  • Astellas Acquires Worldwide Rights for Amevive(r)
  • Biogen Acquires Fumapharm
  • Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy

11. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (USA)
  • Amgen Inc. (USA)
  • Bayer Schering Pharma AG (Germany)
  • Biogen Idec Inc. (USA)
  • Bristol-Myers Squibb Company (USA)
  • Elan Corporation plc (Ireland)
  • Eli Lilly and Company (USA)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Chugai Pharmaceutical Co., Ltd. (Japan)
  • Genentech, Inc. (USA)
  • GlaxoSmithKline Plc (UK)
  • Johnson & Johnson, Inc. (USA)
  • Merck & Co., Inc. (US)
  • Merck Serono SA (Switzerland)
  • Novartis AG (Switzerland)
  • Sanofi-aventis SA (France)
  • Shire Plc (Ireland)
  • Teva Pharmaceuticals Industries Limited (Israel)
  • UCB S.A. (Belgium)

12. GLOBAL MARKET PERSPECTIVE

  • Table 5: World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 6: World Historic Review for Autoimmune Disease Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 7: World 15-year Perspective for Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
  • Table 8: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 9: World Historic Review for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 10: World 15-year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
  • Table 11: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 12: World Historic Review for Multiple Sclerosis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 13: World 15-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
  • Table 14: World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 15: World Historic Review for Psoriasis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 16: World 15-year Perspective for Psoriasis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
  • Table 17: World Recent Past, Current & Future Analysis for Crohn's Disease Therapeutics (Biologicals) by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 18: World Historic Review for Crohn's Disease Therapeutics (Biologicals) by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 19: World 15-year Perspective for Crohn's Disease Therapeutics (Biologicals) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
  • Table 20: World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
  • Table 21: World Historic Review for Other Autoimmune Disease Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
  • Table 22: World 15-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

13. THE UNITED STATES

  • A. Market Analysis
    • Current and Future Analysis
    • Autoimmune Diseases Fact Sheet
    • Table 23: Prevalence of Key Autoimmune Diseases in the US (in Millions) (includes corresponding Graph/Chart)
    • Market Trends
      • Biologic Drugs Lead the Fray
      • Biologics To Add Further Impetus to the Market
      • Rheumatoid Arthritis Drugs Lead the Market
      • Enbrel and Humira Continue to Gain Share in the Anti-TNF Market
      • Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market
    • Table 24: Leading Multiple Sclerosis Drugs in the US (2008): Percentage Share Breakdown of New Prescriptions Written for Avonex, Copaxone, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)
      • Incidence of Type 1 Diabetes Mellitus Endemic in White Youth
      • Lialda's Share Gaining Momentum in Ulcerative Colitis Drugs Market
      • Key Ulcerative Colitis Drugs Market in the US (2006)
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 25: US Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 26: US Historic Review for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 27: US 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment - Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Japanese Patients Exhibit Unique Efficacy & Safety Effects
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 28: Japanese Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 29: Japanese Historic Review for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 30: Japanese 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment - Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Europe - A Burgeoning Market for Autoimmune Disease Therapeutics
      • Increasing Awareness to Drive Market Growth
    • Low Penetration to Fuel Growth in European MS DMDs Market
    • Table 31: Prevalence of Key Autoimmune Diseases in Europe in Millions (includes corresponding Graph/Chart)
    • Lower Treatment Rate Bodes Huge Potential for the UK MS Drug Market
    • Drugs Hindering Disease Progression to Gain Prominence
    • Rising Demand for Rheumatoid Arthritis Drugs in Russia
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 32: European Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 33: European Historic Review for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 34: European 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment - Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

16. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
      • Canada
      • Canada - Highest Prevalence Rates for Multiple Sclerosis
      • Sales of Biologics on the Rise in Canadian Rheumatoid Arthritis Drugs Market
      • Asia-Pacific
      • Autoimmune Diseases Market in Asia-Pacific - An Overview
      • Incidence of Multiple Sclerosis in India on the Rise
      • Overview of Rheumatoid Arthritis in Australia
    • Table 35: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart)
    • Table 36: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Sex (includes corresponding Graph/Chart)
      • Overview of Irritable Bowel Diseases in Australia
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Player
  • B. Market Analytics
    • Table 37: Rest of World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 38: Rest of world Historic Review for Autoimmune Disease Therapeutics by Disease Segment - Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 39: Rest of World 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment - Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Show More
Pricing
Get Notified
Email me when related reports are published